Advances in drug delivery strategies against Helicobacter pylori
10.16438/j.0513-4870.2021-0471
- VernacularTitle:抗幽门螺杆菌递药策略的研究进展
- Author:
Xiao-nan CHEN
;
Ying-ying SUN
;
Peng-yu LI
;
Yi-qin RAO
;
Shi-hui YU
;
Hai-yan HU
- Publication Type:Research Article
- Keywords:
italic>Helicobacter pylori;
bacterial infection;
rug resistance;
eradication;
rug delivery system
- From:
Acta Pharmaceutica Sinica
2021;56(9):2495-2504
- CountryChina
- Language:Chinese
-
Abstract:
italic>Helicobacter pylori (H. pylori) can cause a variety of digestive tract diseases, the serious may develop into gastric cancer. Nowadays, H. pylori infection rate exceeds 50%, and its eradication rate is declining due to the continuous increase of drug resistance, leading to the occurrence of plenty of stubborn infections, which seriously threaten human health. At present, it is difficult to achieve satisfactory curative effect by increasing the types of antibiotics combination or increasing their dose. In this review, the clinical treatments of H. pylori were introduced. Proceed from the characteristics and pathological background of H. pylori infection that makes H. pylori difficult to eradicate, the research advances of drug delivery strategies for improving H. pylori eradication rate were reviewed, such as strategies that could increase drug concentration in stomach (e.g. drug delivery systems with gastric acid-stabilized ability), increase drug concentration in H. pylori colonization sites (e.g. drug delivery systems with gastric retention or H. pylori targeted abilities), overcome H. pylori resistance (metal nanoparticles, anti-biofilm delivery systems), enhance host immune response (vaccine preparation) and so on. Novel drug delivery systems, such as cell membrane coating technology and phage therapy, are comparatively rare in the field of anti-H. pylori, but have broad application prospects. This review would provide reference for the development and application of therapeutic strategies to improve H. pylori eradication rate.
